The Company regularly evaluates its business and objectives to ensure that it is properly configured and sized based on changing market conditions. Accordingly, the Company has implemented certain restructuring initiatives, including consolidation of facilities throughout the world and rationalization of its operations. In the second quarter of fiscal year 2025, management initiated a restructuring plan primarily designed to focus the end market exposure and streamline the operations of the Company's global genomics business.

The Company’s restructuring charges consist of severance payments, costs for outplacement services, and post-employment benefits (collectively, “employee separation costs”), other related exit costs and asset impairment charges related to restructuring activities. These amounts are partially recorded within cost of service revenues and partially recorded within general and administrative expense on the condensed consolidated statements of operations.

Restructuring charges by segment were as follows:


	Three months ended November 30,				Six months ended November 30,
	2024		2023		2024		2023
Food Safety	$	1,504	$	49	$	1,636	$	216
Animal Safety		7,077		1,330		7,077		1,330
Corporate		987		477		1,225		869
Total	$	9,568	$	1,856	$	9,938	$	2,415

Restructuring activity for the six months ended November 30, 2024 was as follows:


	Employee Separation Costs			Other Exit Costs			Total
Balance as of May 31, 2024		-			-			-
Expense		1,983			7,955			9,938
Cash Payments		(516	)		(627	)		(1,143	)
Asset impairments and other		-			(7,328	)		(7,328	)
Balance as of November 30, 2024		1,467			-			1,467